FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2475231534> ?p ?o ?g. }

• W2475231534 endingPage "6325" @default.
• W2475231534 startingPage "6314" @default.
• W2475231534 abstract "ABSTRACT At least 15 high-risk human papillomaviruses (HPVs) are linked to anogenital preneoplastic lesions and cancer. Currently, there are three licensed prophylactic HPV vaccines based on virus-like particles (VLPs) of the L1 major capsid protein from HPV-2, -4, or -9, including the AS04-adjuvanted HPV-16/18 L1 vaccine. The L2 minor capsid protein contains HPV-neutralizing epitopes that are well conserved across numerous high-risk HPVs. Therefore, the objective of our study was to assess the capacity to broaden vaccine-mediated protection using AS04-adjuvanted vaccines based on VLP chimeras of L1 with one or two L2 epitopes. Several chimeric VLPs were constructed by inserting L2 epitopes within the DE loop and/or C terminus of L1. Based on the shape, yield, size, and immunogenicity, one of seven chimeras was selected for further evaluation in mouse and rabbit challenge models. The chimeric VLP consisted of HPV-18 L1 with insertions of HPV-33 L2 (amino acid residues 17 to 36; L1 DE loop) and HPV-58 L2 (amino acid residues 56 to 75; L1 C terminus). This chimeric L1/L2 VLP vaccine induced persistent immune responses and protected against all of the different HPVs evaluated (HPV-6, -11, -16, -31, -35, -39, -45, -58, and -59 as pseudovirions or quasivirions) in both mouse and rabbit challenge models. The degree and breadth of protection in the rabbit were further enhanced when the chimeric L1/L2 VLP was formulated with the L1 VLPs from the HPV-16/18 L1 vaccine. Therefore, the novel HPV-18 L1/L2 chimeric VLP (alone or in combination with HPV-16 and HPV-18 L1 VLPs) formulated with AS04 has the potential to provide broad protective efficacy in human subjects. IMPORTANCE From evaluations in human papillomavirus (HPV) protection models in rabbits and mice, our study has identified a prophylactic vaccine with the potential to target a wide range of HPVs linked to anogenital cancer. The three currently licensed vaccines contain virus-like particles (VLPs) of the L1 major capsid protein from two, four, or nine different HPVs. Rather than increasing the diversity of L1 VLPs, this vaccine contains VLPs based on a recombinant chimera of two highly conserved neutralizing epitopes from the L2 capsid protein inserted into L1. Our study demonstrated that the chimeric L1/L2 VLP is an effective vehicle for displaying two different L2 epitopes and can be used in a quantity equivalent to what is used in the licensed vaccines. Hence, using the chimeric L1/L2 VLP may be a more cost-effective approach for vaccine formulation than adding different VLPs for each HPV." @default.
• W2475231534 created "2016-07-22" @default.
• W2475231534 creator A5009872716 @default.
• W2475231534 creator A5011550497 @default.
• W2475231534 creator A5028003165 @default.
• W2475231534 creator A5038573838 @default.
• W2475231534 creator A5044735919 @default.
• W2475231534 creator A5046111173 @default.
• W2475231534 creator A5053393764 @default.
• W2475231534 creator A5057251015 @default.
• W2475231534 creator A5065112517 @default.
• W2475231534 date "2016-07-15" @default.
• W2475231534 modified "2023-10-14" @default.
• W2475231534 title "Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles" @default.
• W2475231534 cites W1504522629 @default.
• W2475231534 cites W1688784376 @default.
• W2475231534 cites W1859061642 @default.
• W2475231534 cites W1876505025 @default.
• W2475231534 cites W1966676297 @default.
• W2475231534 cites W1981725818 @default.
• W2475231534 cites W1986310806 @default.
• W2475231534 cites W1987350137 @default.
• W2475231534 cites W1990030292 @default.
• W2475231534 cites W1990223055 @default.
• W2475231534 cites W1996266688 @default.
• W2475231534 cites W1999882243 @default.
• W2475231534 cites W2010311675 @default.
• W2475231534 cites W2020386919 @default.
• W2475231534 cites W2032060541 @default.
• W2475231534 cites W2033546933 @default.
• W2475231534 cites W2036475509 @default.
• W2475231534 cites W2041647202 @default.
• W2475231534 cites W2046182783 @default.
• W2475231534 cites W2047368772 @default.
• W2475231534 cites W2047580791 @default.
• W2475231534 cites W2051450136 @default.
• W2475231534 cites W2053440993 @default.
• W2475231534 cites W2068965703 @default.
• W2475231534 cites W2072394092 @default.
• W2475231534 cites W2080927908 @default.
• W2475231534 cites W2084586050 @default.
• W2475231534 cites W2086404290 @default.
• W2475231534 cites W2086463570 @default.
• W2475231534 cites W2091001058 @default.
• W2475231534 cites W2093480157 @default.
• W2475231534 cites W2101026209 @default.
• W2475231534 cites W2119010277 @default.
• W2475231534 cites W2123962939 @default.
• W2475231534 cites W2125112713 @default.
• W2475231534 cites W2125678197 @default.
• W2475231534 cites W2125981651 @default.
• W2475231534 cites W2127043059 @default.
• W2475231534 cites W2132910427 @default.
• W2475231534 cites W2135671488 @default.
• W2475231534 cites W2136236728 @default.
• W2475231534 cites W2139736159 @default.
• W2475231534 cites W2145493570 @default.
• W2475231534 cites W2153696347 @default.
• W2475231534 cites W2158027129 @default.
• W2475231534 cites W2160808472 @default.
• W2475231534 cites W2164710273 @default.
• W2475231534 cites W2166678252 @default.
• W2475231534 cites W2189263758 @default.
• W2475231534 doi "https://doi.org/10.1128/jvi.00449-16" @default.
• W2475231534 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4936133" @default.
• W2475231534 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27147749" @default.
• W2475231534 hasPublicationYear "2016" @default.
• W2475231534 type Work @default.
• W2475231534 sameAs 2475231534 @default.
• W2475231534 citedByCount "27" @default.
• W2475231534 countsByYear W24752315342017 @default.
• W2475231534 countsByYear W24752315342018 @default.
• W2475231534 countsByYear W24752315342019 @default.
• W2475231534 countsByYear W24752315342020 @default.
• W2475231534 countsByYear W24752315342021 @default.
• W2475231534 countsByYear W24752315342022 @default.
• W2475231534 countsByYear W24752315342023 @default.
• W2475231534 crossrefType "journal-article" @default.
• W2475231534 hasAuthorship W2475231534A5009872716 @default.
• W2475231534 hasAuthorship W2475231534A5011550497 @default.
• W2475231534 hasAuthorship W2475231534A5028003165 @default.
• W2475231534 hasAuthorship W2475231534A5038573838 @default.
• W2475231534 hasAuthorship W2475231534A5044735919 @default.
• W2475231534 hasAuthorship W2475231534A5046111173 @default.
• W2475231534 hasAuthorship W2475231534A5053393764 @default.
• W2475231534 hasAuthorship W2475231534A5057251015 @default.
• W2475231534 hasAuthorship W2475231534A5065112517 @default.
• W2475231534 hasBestOaLocation W24752315341 @default.
• W2475231534 hasConcept C104317684 @default.
• W2475231534 hasConcept C121608353 @default.
• W2475231534 hasConcept C123894998 @default.
• W2475231534 hasConcept C141231307 @default.
• W2475231534 hasConcept C159047783 @default.
• W2475231534 hasConcept C159654299 @default.
• W2475231534 hasConcept C195616568 @default.
• W2475231534 hasConcept C202878990 @default.
• W2475231534 hasConcept C203014093 @default.
• W2475231534 hasConcept C2522874641 @default.

• next